Nervgen Pharma Ord Shs
NGEN
View Detailed Chart
3.880USD
+0.050+1.31%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.31%
5 Days
-3.24%
1 Month
0.00%
6 Months
0.00%
Year to Date
0.00%
1 Year
0.00%
View Detailed Chart
TradingKey Stock Score
No stock score available due to insufficient data.
Nervgen Pharma Ord Shs News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Nervgen Pharma Ord Shs Info
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
Ticker SymbolNGEN
CompanyNervgen Pharma Ord Shs
CEORogers (Adam H)
Websitehttps://www.nervgen.com/
Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69358.700
-611.430 (-0.87%)
282.580
+22.390 (+8.61%)
2049.170
-2.560 (-0.13%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
